Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Abdera Therapeutics has raised $142.0M in total funding. The most recent round was Series B. The last funding was announced in April 2023.
Abdera Therapeutics's investors include Versant Ventures, RTW Investments, Qiming Venture Partners USA, Viking Global Investors, Amplitude Venture Capital.
Abdera Therapeutics is headquartered in Vancouver, Canada.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Abdera Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abdera Therapeutics — Funding & Investors." VCBacked, April 20, 2023, https://www.vcbacked.co/company/abdera-therapeutics. Accessed July 18, 2026.
VCBacked. (2023). Abdera Therapeutics — Funding & Investors. Retrieved July 18, 2026, from https://www.vcbacked.co/company/abdera-therapeutics
{{cite web |title=Abdera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/abdera-therapeutics |website=VCBacked |access-date=July 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated